<DOC>
	<DOC>NCT01147692</DOC>
	<brief_summary>This open-label study evaluates the pharmacokinetics of simvastatin when coadministered with albiglutide in healthy adult subjects. The primary objective is to assess the effect of albiglutide doses on the pharmacokinetics of simvastatin.</brief_summary>
	<brief_title>A Drug Interaction Study of Simvastatin and Albiglutide</brief_title>
	<detailed_description>This Phase I open-label study evaluates the pharmacokinetics of simvastatin when coadministered with albiglutide in healthy adult subjects. The primary objective is to assess the effect of albiglutide doses on the pharmacokinetics of simvastatin.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>no clinically significant diseases or clinically significant abnormal laboratory values females must be of nonchildbearing potential body mass index (BMI) is &gt;/=18 kg and â‰¤30 kg/m2 nonsmoker negative drug screen positive test results for hepatitis B, hepatitis C or human immunodeficiency virus (HIV) any clinically relevant abnormality female subject is pregnant or breastfeeding history of any anaphylactic reaction to any drug history of significant cardiovascular or pulmonary dysfunction current or chronic history of liver disease history of alcohol or substance abuse history of thyroid dysfunction or disease history of gastrointestinal surgery or disease history of pancreatitis previously received any GLP1 mimetic compound (e.g., exenatide)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>albiglutide</keyword>
	<keyword>simvastatin</keyword>
	<keyword>healthy volunteers</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>